egfrcancer.org
Continuing Osimertinib Treatment After Progression Prolongs Survival Benefit in NSCLC
*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from The University of Texas MD Anderson Cancer Center (MDACC) and the Moffitt Cancer Center and